Friday 6 November 2026 Export ROIV’s income statement to Excel — free account

Roivant Sciences Ltd.

ROIV Healthcare Biotechnology

Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.

Revenue: −33.6%
EPS: +21.2%
Free cash flow: −30.0%

Quarter to June 2026, against a year earlier

38.90 2.28 +6.23%

Follow ROIV

Alert me

Market cap: $26.5B
P/E: 0.0×
Fwd P/E: −27.7×
Dividend yield: —
F-score: 2/9
Altman Z: 28.31
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Roivant Sciences Ltd. (ROIV) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Roivant Sciences Ltd. (ROIV) trades at a P/S ratio of 3,528×. Over the past ten years it has ranged from 0.0× (March 2021) to 4,001× (September 2026); the current reading is higher than 99% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ROIV/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Roivant Sciences Ltd. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ROIV/metrics/ps-ratio">Roivant Sciences Ltd. (ROIV) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2026	2,355×	834.64%
FY2025	252×	53.74%
FY2024	164×	90.89%
FY2023	85.8×	43.44%
FY2022	59.8×	(76.89%)
FY2021	259×	—

Period	P/S ratio	Change
Jun 2026	3,387×	43.83%
Mar 2026	2,355×	107.25%
Dec 2025	1,136×	124.18%
Sep 2025	507×	53.58%
21 more quarters	Free account

Against its own ten years

Low 0.0× High 4,001×

Ten-year median 176×

Current reading's percentile 99

Company	P/S ratio
INCY Incyte Corporation compare	4.0×
ALNY Alnylam Pharmaceuticals, Inc. compare	4.2×
ONC BeOne Medicines Ltd. - Sponsored ADR compare	6.6×
GMAB Genmab A/S Sponsored ADR compare	7.9×
BNTX BioNTech SE Sponsored ADR compare	7.9×
RPRX Royalty Pharma PLC compare	11.5×
INSM Insmed, Inc. compare	15.6×
RVMD Revolution Medicines, Inc. compare	185×
ROIV Roivant Sciences Ltd.	3,528×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Roivant Sciences Ltd. (ROIV) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ROIV

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ROIV

Stockrow Weekly